Instem PLC's Phil Reason says they've been really busy during lockdown and welcomes new Korea deal

Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy' during the lockdown period as the majority of their revenue comes from clients whose laboratories are regarded as "essential businesses" with many working on COVID-19 related vaccines and therapies.